CRISPR–Cas3 genome-editing system holds therapeutic potential
Genetic disorders occur due to alterations in the primary genetic material—deoxyribonucleic acid (DNA)—of an organism.
Genetic disorders occur due to alterations in the primary genetic material—deoxyribonucleic acid (DNA)—of an organism.
Scientists and physicians can better assess precision genome editing technology using a new method made public today by St. Jude Children's Research Hospital. Significant amounts of time and resources spent improving CRISPR ...
The gene editing tool known as CRISPR-Cas9 is changing what's possible for treating a wide range of diseases caused by genetic mutations. But so far, attempts to use the technology to address brain-based genetic disorders ...
Insects that feed on starch can find veritable feasts in corn, pea, and bean crops or warehouses. It is no coincidence that the ancestors of these commercial plants developed α-amylase inhibitor proteins, which make the starch ...
A team led by University of Pittsburgh's Graham Hatfull has developed a method to construct bacteriophages with entirely synthetic genetic material, allowing researchers to add and subtract genes at will. The findings open ...
Genetically modified organisms, also known as GMOs, have been a hot topic of conversation among researchers, producers, government agencies, and the general public for decades.
Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by chemist Brian Liau and his collaborators at Harvard offers an unprecedented window into this activity, ...
Some genetic disorders—such as cystic fibrosis, hemophilia and Tay Sachs disease—involve many mutations in a person's genome, often with enough variation that even two individuals who share the same disorder might have a ...
One of the most revolutionary tools in cutting-edge medicine is a molecular scalpel so precise that it can modify defective DNA and fix genetic diseases like sickle cell anemia, and chronic disorders like cardiovascular diseases ...
Researchers at Integra Therapeutics, in collaboration with the Pompeu Fabra University (UPF) Department of Medicine and Life Sciences (MELIS) and the Center for Genomic Regulation (CRG), have designed and experimentally validated ...